Transition Bio
Cambridge, US · Founded 2020 · Delaware corporation · 5 known investors
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Founders & leadership
Transition Bio was founded in 2020 by Tuomas Knowles, Samuel Cohen, and G. Kelly Martin.
TK
Tuomas KnowlesExecutive Director, Co-Founder & Chief Technology Officer
SC
Samuel CohenExecutive Director & Co-Founder
GK
G. Kelly MartinExecutive Chairman & Co-Founder
GM
George MartinExecutive
ST
Stephanie TorruellaExecutive
PM
Preet MakkarExecutive
MK
Martin KulanderNamed on SEC filing
GL
Gregory L. MillerNamed on SEC filing
Board
RW
Robert WeeksBoard director
PM
Paxton MajorBoard director
CM
Connor McDermottBoard director
KY
Kathy YiBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$58.4M disclosed across 3 rounds · 2022–2024
▶$13.3MraisedOct 2024 · 8 investors · BiotechnologyRule 506(b)
▶$13.3MraisedOct 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tuomas KnowlesDirector
- Kathy YiDirector
- Robert WeeksDirector
- George MartinExecutive Officer, Director
- Al SandrockDirector
- Stephanie TorruellaExecutive Officer
- Samuel CohenDirector
- Preet MakkarExecutive Officer
- Paxton MajorDirector
- Offering amount
- $21.3M
- Amount sold
- $13.3M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6MraisedJan 2024 · 5 investors · BiotechnologyRule 506(b)
▶$6MraisedJan 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Samuel CohenDirector
- Connor McDermottDirector
- Tuomas KnowlesExecutive Officer, Director
- George MartinExecutive Officer, Director
- Preet MakkarExecutive Officer
- Kathy YiDirector
- Stephanie TorruellaExecutive Officer
- Al SandrockDirector
- Offering amount
- $15M
- Amount sold
- $6M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$39.1MraisedMar 2023 · 22 investors · BiotechnologyRule 506(b)
▶$39.1MraisedMar 2023 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathy YiDirector
- Samuel CohenDirector
- George K. MartinDirector
- Martin KulanderExecutive Officer
- Connor McDermottDirector
- Tuomas KnowlesExecutive Officer
- Gregory L. MillerExecutive Officer, Director
- Al SandrockDirector
- Offering amount
- $50M
- Amount sold
- $39.1M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Transition Bio do?
- Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
- Who founded Transition Bio?
- Transition Bio was founded by Tuomas Knowles, Samuel Cohen, G. Kelly Martin in 2020.
- Who are Transition Bio's investors?
- Transition Bio's investors include Northpond Ventures, Lifeforce Capital, Magnetic Ventures, Taiho Ventures, LLC, Dolby Family Ventures.
- How much funding has Transition Bio raised?
- Transition Bio has disclosed $58.4M raised across 3 rounds.
- Where is Transition Bio headquartered?
- Transition Bio is headquartered in Cambridge, US.